Authors

Sarah M. McLeod, Samir H. Moussa, Meredith Hackel, Carmen Au, Pierre Daram

Source

Authors

Susana Ribeiro, Yanina Nuccetelli, Wanda Cornistein, Maria Ines Staneloni

Source

For more than 20 years, EDCTP has demonstrated the impact of Europe–Africa collaboration — supporting clinical research, strengthening scientific capacity and accelerating the development of health innovations that address poverty-related and neglected diseases. Beyond its role as a research funding instrument, EDCTP serves as a strategic platform connecting Europe’s global health, research and innovation agendas.

As global health challenges evolve, continued investment in EDCTP will be essential to ensure Europe and Africa remain at the forefront of discovery, innovation and preparedness for emerging threats.

Read more about the impact of the collaboration between PDPs and EDCTP, and our joint recommendations, in the new report.

Source

Antimicrobial resistance (AMR) is a major and growing threat to global health, development, and security, with the greatest burden borne by low-income and middle-income countries (LMICs). Without urgent intervention, cumulative deaths between 2020 and 2050, attributable to AMR, are projected to be 39·1 million globally. Effective diagnostics are important to bacterial pathogen detection and antimicrobial susceptibility testing, and such diagnostics support antibiotic stewardship by reducing adverse drug events (eg, toxicity or allergy) and restricting the emergence and spread of AMR. Yet, access to appropriate diagnostics in LMICs remains constrained.

Authors

Valeria Gigante PhD, Maurine Murtagh JD, Prof Till T Bachmann PhD, Tamarie Rocke MD, Betsy W Trainor BSc, Susan M Poutanen MD MPH, Teri Roberts PhD, Prof Jordi Vila MD PhD, Alexandra Cameron PhD

Read publication

Source

Zoliflodacin is a first-in-class oral spiropyrimidinetrione antibiotic being developed for patients with uncomplicated gonorrhea, including those infected with multidrug-resistant strains. Because zoliflodacin is metabolized by cytochrome P450 3A4 (CYP3A4), concomitant administration with a CYP3A inhibitor has the potential to increase zoliflodacin plasma exposure. The aim of this phase 1 drug–drug interaction (DDI) study was to assess the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) and safety of a 3 g single oral dose of zoliflodacin.

Authors

Alison Luckey, Kajal B. Larson, Noha Rayad, Markus Heep, Sophie Delhomme, Gabrielle Kornmann, John P. Mueller, John P. O’Donnell, Seamus O’Brien, Rainard Fuhr, Jean-Yves Gillon

Read publication

Source

Sexually-transmitted pathogens Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) cause curable but often asymptomatic bacterial infections. Missed diagnoses and treatment, leading to chronic infections, can cause clinical complications and increase transmission. Accurate prevalence estimates are essential for the effective public health control of these sexually transmitted infections, especially in Africa, where data are scarce.

Authors

Catherine Ngugi,Borna A. Nyaoke,Leonard Kingwara,Pacific Akinyi,Mildred Mmbone,Thaddaeus W. Egondi,George M. Nyangweso,Helen Broadhurst,Gabrielle Kornmann,Rashmi Mathur ,Esther Bettiol

Read publication

Source

AntibioticDB (https://www.antibioticdb.com/), originally established in 2017 and since 2021 led by the Global Antibiotic Research & Development Partnership (GARDP), is a freely available database of antibacterial agents to facilitate research and development of new antibacterial therapeutics. Here, we describe a new release of AntibioticDB that has been significantly expanded and updated with the aid of user feedback and which offers additional functionality through a redesigned web portal.

Authors

Luiza H. Galarion, Alan Hennessy, Simon D. Harding, Jane F. Armstrong, Astrid Pentz-Murr, Jamie A. Davies, Alex J. O’Neill, Laura J. V. Piddock

Read full article

Source

Neonatal doses for the off-patent antibiotics fosfomycin and flomoxef, flomoxef,which offer coverage against many extended-spectrum beta-lactamase (ESBL)-producing organisms, are based on limited data. We performed a pharmacokinetic (PK) and safety study of fosfomycin and flomoxef to confirm proposed neonatal dosing before further investigation in a trial (NeoSep1, ISRCTN48721236).

Authors

Adrie Bekker, Navarat Panjasawatwong, Louise F. Hill, Wolfgang Stohr, A. Sarah Walker, Sally Ellis, Angela Dramowski, Andrew Whitelaw, Christina Obiero, James A. Berkley, Alexander Makazi, Sithembiso Velaphi, Reenu Thomas, Petronella Magagula, Ilhaam Abrahams, Firdose L. Nakwa, Mohammed M. Barday, Alison Van Kwawegen, Kamla Pillay, Silke Gastine, Joseph F. Standing, Peter Skoutari, Francesca Schiavone, Mike Sharland, Seamus O’Brien, Julia A. Bielicki, Tim R. Cressey, On behalf of the NeoSep Study Team

Read full publication

Source

In 2020, WHO estimated that Neisseria gonorrhoeae caused 82·4 million new cases of gonorrhoea among those aged 15–49 years worldwide. Without effective treatment, the morbidity associated with gonorrhoea complications can be considerable. Additionally, N gonorrhoeae infection enhances the risk of acquiring or transmitting HIV.

N gonorrhoeae has developed resistance to all current and previously used classes of antibiotics used to treat gonorrhoea, with ceftriaxone the sole remaining empirical treatment option for first-line gonorrhoea monotherapy. In 2017–18, the WHO Gonococcal Antimicrobial Surveillance Programme (GASP) reported high global rates of fluoroquinolone resistance, increasing azithromycin resistance, and, worryingly, progressively increasing multidrug resistance, including to extended-spectrum cephalosporins, such as ceftriaxone. Resistance patterns vary considerably by region; the WHO Enhanced GASP has highlighted situations of particular concern in Cambodia and Viet Nam. In 2022, nearly a third of isolates (32%) in Cambodia showed resistance to either broad-spectrum cephalosporins or azithromycin (with 7% showing resistance to both), and in Viet Nam, 27% of isolates were resistant to ceftriaxone in 2023. The WHO global action plan highlighted the development of new antibiotics for gonorrhoea as a high priority, and in 2019 the US Centers for Disease Control and Prevention declared antimicrobial-resistant N gonorrhoeae an urgent public health threat.

Authors

Alison Luckey, Manica Balasegaram, Lindley A Barbee, Teresa A Batteiger, Helen Broadhurst, Stephanie E Cohen, Sinead Delany-Moretlwe, Henry J C de Vries, Jodie A Dionne, Katherine Gill, Chris Kenyon, Rossaphorn Kittiyaowamarn, Drew Lewis, John P Mueller, Vimla Naicker, Seamus O’Brien, John P O’Donnell, Nittaya Phanuphak, Elizabeth Spooner, Subasree Srinivasan, Stephanie N Taylor, Magnus Unemo, Zinhle Zwane, Edward W Hook 3rd, for the Zoliflodacin Phase 3 Study Group*

Read the publication

Source

A fifth of blood cultures from patients with infections acquired in a healthcare setting in South Africa will yield an organism. Carbapenem-resistant Enterobacterales (CREs), specifically Klebsiella pneumoniae are the most predominant Gram-negative bacteria (GNB) isolated among bloodstream infections (BSI). Additionally, the multidrug-resistant nature of these organisms is not only a threat to patients but it also poses a big public health challenge to current treatments and highlights the need for the development of new antimicrobials. Therefore, CRE have been placed on the critical priority list by the World Health Organization (WHO). We aimed to provide a holistic overview of the GERMS-SA CRE BSI surveillance data from 01 July 2015–31 December 2021.

Authors

Husna Ismail, Thembekile Buhle Christna Zwane, Elloise Du Toit, Renata Maria Augusto da Costa, François Franceschi, Olga Perovic

Read the publication

Source